376 related articles for article (PubMed ID: 11255561)
41. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
42. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
43. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
Zujewski J
Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
[TBL] [Abstract][Full Text] [Related]
44. What would be the properties of an ideal SERM?
Anthony M; Williams JK; Dunn BK
Ann N Y Acad Sci; 2001 Dec; 949():261-78. PubMed ID: 11795362
[TBL] [Abstract][Full Text] [Related]
45. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Bryant HU; Dere WH
Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
[TBL] [Abstract][Full Text] [Related]
46. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
47. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
48. ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999).
American College of Obsterticians and Gynecologists Committee on Practice Bulletins-Gynecology
Int J Gynaecol Obstet; 2002 Dec; 79(3):289-98. PubMed ID: 12501867
[TBL] [Abstract][Full Text] [Related]
49. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
50. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.
Gennari L; Merlotti D; Valleggi F; Martini G; Nuti R
Drugs Aging; 2007; 24(5):361-79. PubMed ID: 17503894
[TBL] [Abstract][Full Text] [Related]
51. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
Muchmore DB
Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
[TBL] [Abstract][Full Text] [Related]
52. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Col NF; Pauker SG; Goldberg RJ; Eckman MH; Orr RK; Ross EM; Wong JB
Arch Intern Med; 1999 Jul; 159(13):1458-66. PubMed ID: 10399897
[TBL] [Abstract][Full Text] [Related]
53. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.
O'Regan RM; Jordan VC
Lancet Oncol; 2002 Apr; 3(4):207-14. PubMed ID: 12067682
[TBL] [Abstract][Full Text] [Related]
54. Raloxifene: a review of its use in the prevention of invasive breast cancer.
Moen MD; Keating GM
Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
[TBL] [Abstract][Full Text] [Related]
55. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
[TBL] [Abstract][Full Text] [Related]
56. Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
Lo SS; Vogel VG
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):97-111. PubMed ID: 14687600
[TBL] [Abstract][Full Text] [Related]
57. [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Kobayashi H; Hamaya E
Nihon Yakurigaku Zasshi; 2005 Jan; 125(1):37-48. PubMed ID: 15738620
[No Abstract] [Full Text] [Related]
58. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.
Lufkin EG; Wong M; Deal C
Rheum Dis Clin North Am; 2001 Feb; 27(1):163-85, vii. PubMed ID: 11285993
[TBL] [Abstract][Full Text] [Related]
59. [Raloxifene and breast: from the SERMs concept to its place in clinical practice].
This P; Guyot B
Gynecol Obstet Fertil; 2004 Jan; 32(1):75-84. PubMed ID: 14736604
[TBL] [Abstract][Full Text] [Related]
60. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
